Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes

Bioconjugate Chemistry

Volumn 18, Issue 3, 2007, Pages 929-936

  Kim, Young Seung ^a   He, Zhengjie ^a   Hsieh, Wen Yuan ^a   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; CHLORINE COMPOUNDS; HEART; REACTION INTERMEDIATES; STABILITY; SYNTHESIS (CHEMICAL);

BIODISTRIBUTIONS; CATIONIC COMPLEXES; CATIONICS; CONDITION; HEART IMAGING; LIPOPHILICITY; METABOLIC STABILITY; POST INJECTION; SOLUTION STABILITY; THIONES;

AMINO ACIDS;

CHELATING AGENT; NITRIC ACID DERIVATIVE; STANNOUS CHLORIDE; SUCCINIC ACID; SUCCINIC DIHYDRAZIDE; TECHNETIUM 99M; TECHNETIUM 99M NITRIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATION TRANSPORT; CHELATION; COMPLEX FORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; EVALUATION; FECES ANALYSIS; HEART; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; LIPOPHILICITY; LIVER; METABOLIC REGULATION; MOLECULAR STABILITY; NONHUMAN; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE DISTRIBUTION; RAT; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 34347337716     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0603182     Document Type: Article

References (35)

1. 99mTc-nitrido complexes as new radiopharmaceuticals for heart imaging. Nucl. Med. Biol. 33, 419-432.
2. 99mTc heterocomplexes as heart imaging agents with improved biological properties. Nucl. Med. Commun. 23, 689-693.
3. 99mTc-nitride heterocomplexes showing high heart uptake and improved imaging properties. J. Nucl. Med. 44, 806-814.
4. 99mTc-tetrofosmin in rats. J. Nucl. Med. 45, 2095-2101.
5. 2O. A facial geometry imposed by extensive hydrogen bonding with the ice 1 structure. J. Am. Chem. Soc. 109, 4121-4123.
6. Bernstein, L. R., Tanner, T., Godfrey, C., and Noll, B. (2000) Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal Based Drugs 7, 33-47.
7. Matsuba, C. A., Nelson, W. O., Rettig, S. J., and Orvig, C. (1988) Neutral water-soluble indium complexes of 3-hydroxy-4-pyrones and 3-hydroxy-4-pyridinones. Inorg. Chem. 27, 3935-3939.
8. 2O (Hema = 2-Ethyl-3-Hydroxy-4-Pyrone. Inorg. Chim. Acta 359, 228-236.
9. 2O (DMHP = 1,2-dimethyl-3- hydroxy-4-pyridinone). Inorg. Chem. 44, 2031-2038.
10. Hsieh, W. Y., and Liu, S. (2005) Synthesis, characterization and structures of Cr(III) complexes with 3-hydroxy-4-pyrones and 1,2-dimethyl-3-hydroxy-4-pyridinone. Synth. React. Inorg., Met.-Org. Chem. 35, 61-70.
11. McNeill, J. H., Yuen, V. G., Hoveyda, H. R., and Orvig, C. (1992) Bis(maltolato)-oxovanadium(IV) is a potent insulin mimic. J. Med. Chem. 35, 1489-1491.
12. Caravan, P., Gelmini, L., Glover, N., Herring, F. G., Li, H. L., McNeill, J. H., Rettig, S. J., Setyawati, I. A., Shuter, E., Sun, Y., Tracey, A. S., Yuen, V. G., and Orvig, C. (1995) Reaction chemistry of BMOV, bis(maltolato)oxovanadium(IV), a potent insulin mimetic agent. J. Am. Chem. Soc. 117, 12759-12770.
13. Thompson, K. H., and Orvig, C. (2001) Coordination chemistry of vanadium in metallopharmaceutical candidate compounds. Coord. Chem. Rev. 219, 1033-1053., references therein.
14. Thompson, K. H., and Orvig, G (2000) Design of vanadium compounds as insulin enhancing agents. J. Chem. Soc., Dalton Trans. 2885-2892; references therein.
15. 3 Structural isomers. Inorg. Chem. 44, 2689-2697.
16. Thompson, K. H., Chiles, J., Yuen, V. G., Tse, J., McNeill, J. H., and Orvig, C. (2004) Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes. J. Inorg. Biochem. 98, 683-690.
17. Lewis, J. A., Puerta, D. T., and Cohen, S. M. (2003) Metal complexes of the trans-Influencing ligand thiomaltol. Inorg. Chem. 42, 7455-7459.
18. Lewis, J. A., and Cohen, S. M. (2004) Addressing lead toxicity: complexation of lead(II) with thiopyrone and hydroxypyridinthione O, S mixed chelators. Inorg. Chem. 43, 6534-6536.
19. Monga, V., Patrick, B. O., and Orvig, C. (2005) Group 13 and lanthanide complexes with mixed O, S anionic ligands derived from maltol. Inorg. Chem. 44, 2666-2677.
20. Monga, V., Thompson, K. H., Yuen, V. G., Sharma, V., Patrick, B. O., McNeil, J. H., and Orvig, C. (2005) Vanadium complexes with mixed O,S anionic ligands derived from maltol: synthesis, characterization, and biological studies. Inorg. Chem. 44, 2678-2688.
21. Lewis, J. A., Tran, B. L., Puerta, D. T., Rumberger, E. M., Hendrickson, D. N., and Cohen, S. M. (2005) Synthesis, structure and spectroscopy of new thiopyrone and hydroxypyridinethione transition metal complexes. Dalton Trans. 2588-2596.
22. Jones, A. G., Abrams, M. J., Davison, A., Brodack, J. W., Toothaker, A. K., Adelstein, S. J., and Kassis, A. I. (1984) Biological studies of a new class of technetium complexes: the hexakis-(alkylisonitrile)technetium(I) cations. Int. J. Nucl. Biol 11, 225-234.
23. 2en = N,N′-ethylenebis[acetylacetone iminatol]). Nucl. Med. Biol. 26, 755-770; references therein.
24. - = thiolate). J. Med. Chem. 39, 1253-1261.
25. + complexes containing ether analogs of DMPE. Nucl. Med. Biol. 26, 563-571.
26. Jain, D. (1999) Technetium-99m labeled myocardial perfusion imaging agents. Semin. Nucl. Med. 29, 221-236.
27. Acampa, W., Di Benedetto, C., and Cuocolo, A. (2000) An overview of radiotracers in nuclear cardiology. J. Nucl. Cardiol. 7, 701-707.
28. Beller, G. A., and Zaret, B. L. (2000) Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 101, 1465-1478.
29. Banerjee, S., Pillai, M. R. A., and Ramamoorthy, N. (2001) Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med. 31, 260-277.
30. Llaurado, J. G. (2001) The quest for the perfect myocardial perfusion indicator... still a long way to go. J. Nucl. Med. 42, 282-284.
31. Mousa, S. A., Cooney, J. M., and Williams, S. J. (1987) Flow-distribution characteristics of Tc-99m-Hexakis-2-methoxy-2-methylpropyl isonitrile in animal-models of myocardial-ischemia and perfusion (abstract). J. Am. Coll. Cardiol. 9, A137.
32. Piwnica-Worms, D., Kronauge, J. F., and Chiu, M. L. (1990) Uptake and retention of hexakis(2-methoxyisobutylisonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 82, 1826-1838.
33. Carvalho, P. A., Chiu, M. L., Kronauge, J. F., Kawamura, M., Jones, A. G., Holman, B. L., and Piwnica-Worms, D. (1992) Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J. Nucl. Med. 33, 1516-1521.
34. Crane, P., Laliberte, R., Heminway, S., Thoolen, M., and Orlandi, G (1993) Effect of mitochondrial viability and metabolism on technetium-99m- sestamibi myocardial retention. Eur. J. Nucl. Med. 20, 20-25.
35. Herman, L. W., Sharma, V., Kronauge, J. F., Barbarics, E., Herman, L. A., and Piwnica-Worms, D. (1995) Novel hexakis-(arenisonitriles)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J. Med. Chem. 38, 2955-2936.